Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for severe lung disease. The Company’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD (chronic obstructive pulmonary disease) who,...
Replimune group, Inc. (NASDAQ: REPL) is leveraging the power of its proprietary Immulytic platform to create a leading-edge oncolytic immunotherapy program that can generate a patient-specific local as well as systemic immune response. The therapies not only fight against the current cancer but also eliminate...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is in the spotlight after receiving a “Buy” rating along with a $30 price target from Ram Selvaraju an analyst at H.C Wainwright, implying a nearly 275% upside from its current levels. We take a look at reasons for the...
Pulmatrix Inc (NASDAQ: PULM), a Clinical Stage Biopharmaceutical Company developing inhaled therapies for the treatment of pulmonary diseases, announced the signing of a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson (NYSE: JNJ), enabling the initiative to access the Company’s...
Artificial Intelligence is making inroads into every segment of the economy including medicine and surgery. Intuitive Surgical Inc. (NASDAQ:ISRG), the market leader in robotic surgery, commands $3.3 billion in annual sales, and the numbers are going to increase manifold in the near future. Companies like...
